Leonteq Securities’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,912
Closed -$60.1K – 1311
2026
Q2
$60.1K Sell
1,912
-2,056
-52% -$60.7K ﹤0.01% 772
2026
Q1
$98.2K Buy
3,968
+1,707
+75% +$40.7K ﹤0.01% 738
2025
Q4
$52.8K Hold
2,261
– – ﹤0.01% 945
2025
Q3
$44.5K Sell
2,261
-439
-16% -$9.03K ﹤0.01% 901
2025
Q2
$58.6K Sell
2,700
-23
-0.8% -$543 ﹤0.01% 821
2025
Q1
$65.8K Sell
2,723
-502
-16% -$11.3K ﹤0.01% 793
2024
Q4
$69.2K Sell
3,225
-84
-3% -$1.8K ﹤0.01% 760
2024
Q3
$65.8K Buy
3,309
+1,266
+62% +$23.5K 0.01% 706
2024
Q2
$31.6K Buy
2,043
+98
+5% +$1.53K ﹤0.01% 849
2024
Q1
$31K Buy
+1,945
New +$29.3K ﹤0.01% 858
2022
Q3
– Sell
-4,000
Closed -$28K – 1294
2022
Q2
$28K Buy
+4,000
New +$29.3K ﹤0.01% 934
2021
Q4
– Sell
-4,000
Closed -$21.2K – 1272
2021
Q3
$21.2K Hold
4,000
– – ﹤0.01% 982
2021
Q2
$23K Buy
+4,000
New +$20.6K ﹤0.01% 931

Other funds holding CPRX

Leonteq Securities's CPRX Position: Q3 2026 in Review

Leonteq Securities sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 1,912 shares — an estimated $60.1K sold.

Leonteq Securities first reported a position in CPRX in Q2 2021 and held it in 13 quarters. The position peaked at $98.2K in Q1 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • Leonteq Securities reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Leonteq Securities sold 1,912 Catalyst Pharmaceutical shares in Q3 2026, an estimated $60.1K.
  • Leonteq Securities first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 13 quarters.
  • Leonteq Securities's Catalyst Pharmaceutical position peaked at $98.2K in Q1 2026.
  • 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.